As autophagy-related genes are highly expressed in early AD, enhanced autophagy may be a promising research area for achieving neuroprotection in AD patients (Moujalled et al., 2021)
But Lilly has to be considered the biggest beneficiary, as its drug tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, became the world's best-selling drug late last year, surpassing Keytruda, a cancer treatment manufactured by Merck
(4) Changes in prescribing trends have been facilitated by a growing number of available GLP-1 receptor agonists, with currently ten agents approved for clinical use
Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes/Leigh overlap syndrome due to variant m
For those with commercial plans that still cover obesity drugs, your costsharing (copay or coinsurance) will depend on your plans design, but the lower negotiated prices may help keep your portion in check
GLP-1 Support Squad | Weight Loss Medication Community